Danaher (DHR) Stock Upgraded on Biotech and Diagnostics Growth Outlook

Danaher Corporation (NYSE:DHR) ranks among the best non-tech stocks to buy according to billionaires. On July 11, Scotiabank set a price target of $275 and upgraded Danaher Corporation (NYSE:DHR) from Sector Perform to Sector Outperform. The update reflects Scotiabank’s optimistic assessment of Danaher’s position in late-stage development and bioprocessing expenditures for the biotech and pharmaceutical industries, in addition to its diagnostics business.

Danaher (DHR) Stock Upgraded on Biotech and Diagnostics Growth Outlook

Danaher Corporation (NYSE:DHR) largely stuck to its year-end guidance following the company’s first quarter 2025 results. Over the next 12 to 18 months, Scotiabank believes Danaher will remain on track to accelerate its growth profile, possibly achieving its long-term goal of a high single-digit top-line compound annual growth rate.

Additionally, the firm emphasized Danaher’s improved alignment with end markets that are expanding rapidly and its operational execution capabilities through the Danaher Business System.

A world leader in science and technology, Danaher Corporation (NYSE:DHR) specializes in biotechnology, life sciences, and diagnostics. The company offers lab apparatus, bioprocessing technology, and diagnostic instruments to improve human health.

While we acknowledge the potential of DHR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than DHR and that has 100x upside potential, check out our report about this cheapest AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.